ProQR Therapeutics N.V. (NASDAQ:PRQR) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.
According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “
PRQR has been the subject of several other reports. ValuEngine raised ProQR Therapeutics N.V. from a “sell” rating to a “hold” rating in a research note on Friday, September 15th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of ProQR Therapeutics N.V. in a research note on Tuesday, September 26th. Chardan Capital reaffirmed a “neutral” rating on shares of ProQR Therapeutics N.V. in a research note on Sunday, September 17th. Leerink Swann reiterated an “outperform” rating and set a $12.00 target price (up previously from $10.00) on shares of ProQR Therapeutics N.V. in a report on Tuesday, September 26th. Finally, JMP Securities increased their target price on ProQR Therapeutics N.V. from $14.00 to $20.00 and gave the company an “outperform” rating in a report on Tuesday, September 26th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $19.38.
ProQR Therapeutics N.V. (NASDAQ PRQR) opened at $3.00 on Wednesday. ProQR Therapeutics N.V. has a one year low of $2.90 and a one year high of $6.90. The company has a quick ratio of 8.22, a current ratio of 8.22 and a debt-to-equity ratio of 0.17.
TRADEMARK VIOLATION WARNING: This piece was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2017/11/15/proqr-therapeutics-n-v-prqr-cut-to-sell-at-zacks-investment-research.html.
Hedge funds have recently bought and sold shares of the company. Nine Chapters Capital Management LLC acquired a new stake in shares of ProQR Therapeutics N.V. during the third quarter worth $133,000. Wells Fargo & Company MN boosted its holdings in ProQR Therapeutics N.V. by 212.6% in the third quarter. Wells Fargo & Company MN now owns 43,226 shares of the biopharmaceutical company’s stock valued at $210,000 after acquiring an additional 29,400 shares during the last quarter. Janus Henderson Group PLC acquired a new position in ProQR Therapeutics N.V. in the second quarter valued at $2,028,000. Artal Group S.A. boosted its holdings in ProQR Therapeutics N.V. by 25.0% in the second quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock valued at $2,600,000 after acquiring an additional 100,000 shares during the last quarter. Finally, Sphera Funds Management LTD. boosted its holdings in ProQR Therapeutics N.V. by 60.6% in the third quarter. Sphera Funds Management LTD. now owns 530,000 shares of the biopharmaceutical company’s stock valued at $2,571,000 after acquiring an additional 200,000 shares during the last quarter. Institutional investors and hedge funds own 36.00% of the company’s stock.
ProQR Therapeutics N.V. Company Profile
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein.
Receive News & Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related companies with MarketBeat.com's FREE daily email newsletter.